Skin Signs of Systemic Disease in Childhood

Advances in Dermatology

Volumn 22, Issue , 2006, Pages 1-30

  Gilliam, Amy E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHILD; CHURG STRAUSS SYNDROME; DERMATOMYOSITIS; HUMAN; LOCALIZED SCLERODERMA; PATHOLOGY; REVIEW; SKIN BLOOD VESSEL DISORDER; SKIN DISEASE; SKIN LUPUS ERYTHEMATOSUS; SYSTEMIC LUPUS ERYTHEMATOSUS;

CHILD; CHURG-STRAUSS SYNDROME; DERMATOMYOSITIS; HUMANS; LUPUS ERYTHEMATOSUS, CUTANEOUS; LUPUS ERYTHEMATOSUS, SYSTEMIC; SCLERODERMA, LOCALIZED; SKIN DISEASES; SKIN DISEASES, VASCULAR;

EID: 33845617294     PISSN: 08820880     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.yadr.2006.08.003     Document Type: Review

References (83)

1. Mendez E.P., Lipton R., Ramsey-Goldman R., et al. US incidence of juvenile dermatomyositis, 1995-1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Rheum 49 (2003) 300-305
2. Wargula J.C. Update on juvenile dermatomyositis: new advances in understanding its etiopathogenesis. Curr Opin Rheumatol 15 (2003) 595-601
3. Reed A.M., McNallan K., Wettstein P., et al. Does HLA-dependent chimerism underlie the pathogenesis of juvenile dermatomyositis?. J Immunol 172 (2004) 5041-5046
4. Peloro T.M., Miller O.F., Hahn T.F., et al. Juvenile dermatomyositis: a retrospective review of a 30-year experience. J Am Acad Dermatol 45 1 (2001) 28-34
5. Santmyire-Rosenberger B., and Dugan E.M. Skin involvement in dermatomyositis. Curr Opin Rheumatol 15 6 (2003) 714-722
6. Mahe E., Descamps V., Burnouf M., et al. A helpful clinical sign predictive of cancer in adult dermatomyositis: cutaneous necrosis. Arch Dermatol 139 4 (2003) 539
7. Callen J.P. Relation between dermatomyositis and polymyositis and cancer. Lancet 357 9250 (2001) 85-86
8. Fisler R.E., Liang M.G., Fuhlbrigge R.C., et al. Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J Am Acad Dermatol 47 (2002) 505-511
9. Mukamel M., Horev G., and Minouni M. New insight into calcinosis of juvenile dermatomyositis. J Pediatr 138 (2001) 763-766
10. Kavanagh G.M., Colaco C.B., and Kennedy C.T. Juvenile dermatomyositis associated with partial lipoatrophy. J Am Acad Dermatol 28 (1993) 348-351
11. Quecedo E., Febrer I., Serrano G., et al. Partial lipodystrophy associated with juvenile dermatomyositis: report of two cases. Pediatr Dermatol 13 (1996) 477-482
12. Huemer C., Kitson H., Malleson P.N., et al. Lipodystrophy in patients with juvenile dermatomyositis-evaluation of clinical and metabolic abnormalities. J Rheumatol 28 (2001) 610-615
13. Buka R.L., and Cunningham B.B. Connective tissue disease in children. Pediatr Ann 34 (2005) 225-229
14. Huber A.M., Lang B., LeBlanc C.M., et al. Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum 43 3 (2000) 541-549
15. Ramanan A.V., Campbell-Webster N., Ota S., et al. The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids. Arthritis Rheum 52 (2005) 3570-3578
16. El-Azahary R.A., and Pakzad S.Y. Amyopathic dermatomyositis: retrospective review of 37 cases. J Am Acad Dermatol 46 (2002) 560-565
17. Frances C., Niang S., Laffitte E., et al. Dermatologic manifestations of the antiphospholipid syndrome: two hundred consecutive cases. Arthritis Rheum 52 (2005) 1785-1793
18. Toubi E., Krause I., Fraser A., et al. Livedo reticularis is a marker for predicting multi-system thrombosis in antiphospholipid syndrome. Clin Exp Rheumatol 23 (2005) 499-504
19. Stichweh D., Arce E., and Pascual V. Update on pediatric systemic lupus erythematosus. Curr Opin Rheumatol 16 (2004) 577-587
20. Jones E.M., and Callen J.P. Collagen vascular diseases of childhood. Pediatr Clin North Am 38 (1991) 1039
21. Abe M., Ishikawa O., and Miyachi Y. Linear cutaneous lupus erythematosus following the lines of Blaschko. Br J Dermatol 139 (1998) 307-310
22. Moises-Alfaro C., Berron-Perez R., Carrasco-Daza D., et al. Discoid lupus erythematosus in children: clinical, histopathologic, and follow-up features in 27 cases. Pediatr Dermatol 20 (2003) 103-107
23. Reichlin M., Broyles T.F., Hubscher O., et al. Prevalence of autoantibodies to ribosomal P proteins in juvenile-onset systemic lupus erythematosus compared with the adult disease. Arthritis Rheum 42 (1999) 69-75
24. Carreno L., Lopez-Longo F.J., Gonzalez C.M., et al. Treatment options for juvenile-onset systemic lupus erythematosus. Paediatr Drugs 4 4 (2002) 241-256
25. Ginzler E.M., Dooley M.A., Aranow C., et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 353 (2005) 2219-2228
26. Buratti S., Szer I.S., Spencer C.H., et al. Mycophenolate mofetil treatment of severe renal disease in pediatric onset systemic lupus erythematosus. J Rheumatol 28 (2001) 2103-2108
27. Fu Y.F., and Liu G.L. Mycophenolate mofetil therapy for children with lupus nephritis refractory to both intravenous cyclosphosphamide and cyclosporine. Clin Nephrol 55 (2001) 318-321
28. Falcini F. Vascular and connective tissue diseases in the paediatric world. Lupus 13 (2004) 77-84
29. Manzi S. Systemic lupus erythematosus: a model for atherogenesis?. Rheumatology (Oxford) 39 (2000) 866-872
30. Boh E.E. Neonatal lupus erythematosus. Clin Dermatol 22 (2004) 125-128
31. Buyon J.P., and Clancy R.M. Neonatal lupus syndromes. Curr Opin Rheumatol 15 (2003) 535-541
32. Luo S.F., Huang C.C., and Wang J.W. Neonatal lupus erythematosus: report of a case. Taiwan Yi Xue Hui Za Zhi 88 8 (1989) 832-835
33. Salomonsson S., Dorner T., Theander E., et al. A serologic marker for fetal risk of congenital heart block. Arthritis Rheum 46 (2002) 1233-1241
34. Chu P., Connolly M.K., and LeBoit P.E. The histopathologic spectrum of palisaded neutrophilic and granulomatous dermatitis in patients with collagen vascular disease. Arch Dermatol 130 (1994) 1278-1283
35. Martin J.A., and Jarrett P. Rheumatoid papules treated with dapsone. Clin Exp Dermatol 29 (2004) 387-389
36. Graham J.A., Hansen K.K., Rabinowitz L.G., et al. Pyoderma gangrenosum in infants and children. Pediatr Dermatol 11 (1994) 10-17
37. Bhat R.M., Shetty S.S., and Kamath G.H. Pyoderma Gangrenosum in childhood. Int J Dermatol 43 (2004) 205-207
38. Al-Rimawi H.S., Abuekteish F.M., Daoud A.S., et al. Familial pyoderma gangrenosum presenting in infancy. Eur J Pediatr 155 (1996) 759-762
39. Herron M.D., Coffin C.M., and Vanderhooft S.L. Sweet syndrome in two children. Pediatr Dermatol 22 6 (2005) 525-529
40. Hwang S.T., Williams M.L., McCalmont T.H., et al. Sweet's syndrome leading to acquired cutis laxa (Marshall's syndrome) in an infant with alpha 1-antitrypsin deficiency. Arch Dermatol 131 10 (1995) 1175-1177
41. Kuniyuki S., and Asada M. An ulcerated lesion at the BCG vaccination site during the course of Kawasaki disease. J Am Acad Dermatol 37 (1997) 303-304
42. Sinha R., and Balakumar T. BCG reactivation: a useful diagnostic tool even for incomplete Kawasaki disease. Arch Dis Child 90 9 (2005) 891
43. Eberhard B.A., Sundel R.P., Newburger J.W., et al. Psoriatic eruption in Kawasaki disease. J Pediatr 137 (2000) 578-580
44. Boralevi F., Barat P., Lepreux S., et al. Kawasaki's disease with eruptive pustular and guttate psoriasis. Ann Dermatol Venereol 130 5 (2003) 528-531
45. Esper F., Shapiro E.D., Weibel C., et al. Association between a novel human coronavirus and Kawasaki disease. J Infect Dis 191 (2005) 499-502
46. Shimizu C., Shike H., Baker S.C., et al. Human coronavirus NL63 is not detected in the respiratory tracts of children with acute Kawasaki disease. J Infect Dis 192 (2005) 1767-1771
47. Fujita Y., Nakamura Y., Sakata K., et al. Kawasaki disease in families. Pediatrics 84 (1989) 666-669
48. Ayusawa M., Sonobe T., Uemura S., et al. Kawasaki Disease Research Committee. Revision of diagnostic guidelines for Kawasaki disease (the 5th revised edition). Pediatr Int 47 (2005) 232-234
49. Falcini F. Kawasaki disease. Curr Opin Rheumatol 18 (2006) 33-38
50. Burns J.C., and Glode M.P. Kawasaki syndrome. Lancet 364 (2004) 533-544
51. Kato H., Sugimura T., Akagi T., et al. Long-term consequences of Kawasaki disease. A 10- to 21- year follow-up study of 594 patients. Circulation 94 (1996) 1379-1385
52. Yeung R.S. Pathogenesis and treatment of Kawasaki's disease. Curr Opin Rheumatol 17 (2005) 617-623
53. Lang B.A., Yeung R.S., Oen K.G., et al. Corticosteroid treatment of refractory Kawasaki Disease. J Rheumatol 33 4 (2006) 803-809
54. Ahn S.Y., and Kim D.S. Treatment of intravenous immunoglobulin-resistant Kawasaki disease with methotrexate. Scand J Rheumatol 34 2 (2005) 136-139
55. Burns J.C., Mason W.H., Hauger S.B., et al. Infliximab treatment for refractory Kawasaki syndrome. J Pediatr 146 (2005) 662-667
56. Trapani S., Micheli A., and Grisolia F. Henoch Schonlein Purpura in childhood: epidemiological and clinical analysis of 150 cases over a 5-year period and review of the literature. Semin Arthritis Rheum 35 (2005) 143-153
57. Sano H., Izumida M., Shimizu H., et al. Risk factors of renal involvement and significant proteinuria in Henoch-Schonlein purpura. Eur J Pediatr 161 (2002) 196-201
58. Van Hale H.M., Gibson L.E., and Schroeter A.L. Henoch-Schonlein vasculitis: direct immunofluorescence study of uninvolved skin. J Am Acad Dermatol 15 4 Pt 1 (1986) 665-670
59. Huber A.M., King J., McLaine P., et al. A randomized, placebo-controlled trial of prednisone in early Henoch Schonlein Purpura. BMC Med 2 (2004) 7
60. Saraclar Y., Tinaztepe K., Adalioglu G., et al. Acute hemorrhagic edema of infancy (AHEI)-a variant of Henoch-Schonlein purpura or a distinct clinical entity?. J Allergy Clin Immunol 86 (1990) 473-483
61. Smitt J.H., Vermeer M.H., and Faber W.R. Acute hemorrhagic edema of infancy (AHEI). Clin Dermatol 20 1 (2002) 2-3
62. Krause I., Lazarov A., Rachmel A., et al. Acute haemorrhagic oedema of infancy, a benign variant of leucocytoclastic vasculitis. Acta Paediatr 85 (1996) 114-117
63. Cox N.H. Seidlmayer's syndrome: postinfectious cockade purpura of early childhood. J Am Acad Dermatol 26 2 Pt 1 (1992) 275
64. Lovell D.J., Bowyer S.L., and Solinger A.M. Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disorder. Arthritis Rheum 52 (2005) 1283-1286
65. Kilcline C., Shinkai K., Bree A., et al. Neonatal-onset multisystem inflammatory disorder: the emerging role of pyrin genes in autoinflammatory disesase. Arch Dermatol 141 (2005) 248-263
66. Hull K.M., Shoham N., Chae J.J., et al. The expanding spectrum of systemic autoinflammatory disorders and their rheumatic manifestations. Curr Opin Rheumatol 15 (2003) 61-69
67. Zulian F, Athreya BH, Laxer R, et al. Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study. Rheumatology (Oxford) 2005 [Epub ahead of print].
68. Marzano A.V., Menni S., Parodi A., et al. Localized scleroderma in adults and children. Clinical and laboratory investigations on 239 cases. Eur J Dermatol 13 2 (2003) 171-176
69. Peterson L.S., Nelson A.M., Su W.P., et al. The epidemiology of morphea (localized scleroderma) in Olmsted County 1960-1993. J Rheumatol 24 1 (1997) 73-80
70. Zulian F., Vallongo C., Woo P., et al. Juvenile Scleroderma Working Group of the Pediatric Rheumatology European Society (PRES). Localized scleroderma in childhood is not just a skin disease. Arthritis Rheum 52 9 (2005) 2873-2881
71. Blaszczyk M., Krolicki L., Jrasu M., et al. Progressive facial hemiatrophy: central nervous system involvement and relationship with scleroderma en coup de sabre. J Rheumatol 30 (2003) 1997-2004
72. Muchnick R.S., Aston S.J., and Rees T.D. Ocular manifestations and treatment of hemifacial atrophy. Am J Ophthalmol 88 (1979) 889-897
73. Cosnes A., Anglade M.C., Revuz J., et al. Thirteen-megahertz ultrasound probe: its role in diagnosing localized scleroderma. Br J Dermatol 148 4 (2003) 724-729
74. Martini G., Murray K.J., Howell K.J., et al. Juvenile-onset localized scleroderma activity detection by infrared thermography. Rheumatology (Oxford) 41 10 (2002) 1178-1182
75. Cunningham BB, Landells ID, Langman C, et al. Topical calcipotriene for morphea/linear scleroderma. J Am Acad Dermatol 1998;39(2 Pt 1):211-5.
76. Kerscher M., Volkenandt M., Gruss C., et al. Low-dose UVA phototherapy for treatment of localized scleroderma. J Am Acad Dermatol 38 1 (1998) 21-26
77. Kreuter A., Gambichler T., Avermaete A., et al. Combined treatment with calcipotriol ointment and low-dose ultraviolet A1 phototherapy in childhood morphea. Pediatr Dermatol 18 3 (2001) 241-245
78. Breuckmann F., Gambichler T., Altmeyer P., et al. UVA/UVA1 phototherapy and PUVA photochemotherapy in connective tissue diseases and related disorders: a research based review. BMC Dermatol 4 1 (2004) 11
79. Kreuter A., Hyun J., Stucker M., et al. A randomized controlled study of low-dose UVA1, medium-dose UVA1, and narrowband UVB phototherapy in the treatment of localized scleroderma. J Am Acad Dermatol 54 3 (2006) 440-447
80. Uziel Y., Feldman B.M., Krafchik B., et al. Methotrexate and corticosteroid therapy for pediatric localized scleroderma. J Pediatr 136 1 (2000) 91-95
81. Harper J.I., Sampaio C., Visentin M.T., et al. Morphoea (localized scleroderma): assessment of disease activity and evaluation of treatment using systemic steroids and methotrexate. Br J Dermatol 153 (2005) 1-8
82. Meneghesso D, Falcini F, Martini G, et al. A prospective clinical and pathological study on the efficacy of combined methotrexate/corticosteroid treatment in juvenile localized scleroderma. Abstract 1411, American College of Rheumatology meeting. San Diego, California, November 13-17, 2005.
83. Oh C.K., Lee J.L., Jang B.S., et al. Treatment of atrophies secondary to trilinear scleroderma en coup de sabre by autologous tissue cocktail injection. Dermatol Surg 29 (2003) 1073-1075